Encouraged by Early Clinical Studies, A Biotech Company Expands Its HIV/AIDS Vaccine Program
Tuesday, April 12, 2011 - 06:30
in Health & Medicine
The HIV Vaccine Trials Network plans to clinically test a novel vaccine product developed by GeoVax scientists that expresses human granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with inactivated HIV proteins.